טוען...
Two Drug Interaction Studies of Sirolimus in Combination with Sorafenib or Sunitinib in Patients with Advanced Malignancies
PURPOSE: Sirolimus is the prototypical mammalian target of rapamycin inhibitor. Sorafenib and sunitinib are small molecule inhibitors of multiple kinases including vascular endothelial receptor kinases (VEGFR). These agents have different mechanisms of action providing a strong rationale for combina...
שמור ב:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2011
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3077032/ https://ncbi.nlm.nih.gov/pubmed/21447721 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-2061 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|